About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Tennessee | 343 Studies

Clinical Trials MelanomaTennessee

Melanoma Clinical Trials in Tennessee

Find 343 clinical trials for melanoma near Tennessee. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 301-320 of 343 trials

CompletedSubstudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.NCT04305041·Los Angeles, California and 35 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedSafety Study of MGA271 in Refractory CancerThe purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer.NCT01391143·Los Angeles, California and 11 others

CompletedA Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerThe purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other…NCT02857270·Washington D.C., District of Columbia and 12 others

TerminatedNivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II ExpressionThis is an open-label, non-randomized two arm Phase 2 study of intravenous nivolumab plus intravenous ipilimumab or intravenous relatlimab in patients with metastatic melanoma…NCT03724968·Nashville, Tennessee

CompletedPH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced MelanomaThe purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab in combination with Ipilimumab treatment on the biomarkers measured in the peripheral…NCT01621490·Los Angeles, California and 13 others

TerminatedTrial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant MelanomaThis phase 2 clinical trial randomizes patients with BRAF mutant melanoma to either (1) standard of care (SOC) - BRAF inhibitor vemurafenib in combination with MEK inhibitor…NCT01495988·Los Angeles, California and 13 others

CompletedA Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive MelanomasThis is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule…NCT04551352·Boston, Massachusetts and 13 others

TerminatedIDO Inhibitor Study for Relapsed or Refractory Solid TumorsThis study provides an early evaluation of an entirely new class of small molecule agents directed at disruption or elimination of tumor tolerance, a phenomenon now demonstrated…NCT00739609·Nashville, Tennessee

CompletedAn Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's LymphomaThis first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of…NCT02783300·Denver, Colorado and 14 others

CompletedAn Appearance-Based Intervention to Reduce Teen Skin Cancer RiskThe purpose of this study is to determine whether a skin cancer prevention website is effective at reduce female teenagers' desire to use indoor tanning and ultimately their use…NCT01508013·Johnson City, Tennessee

TerminatedFDG-PET in Advanced MelanomaThis clinical trial studies how well FDG-PET/CT measures early response in patients with stage III-IV melanoma who are receiving chemotherapy.NCT02236546·Nashville, Tennessee

CompletedA Study of PRT1419 in Patients With Advanced Solid TumorsThis is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with advanced solid tumors.NCT04837677·Denver, Colorado and 6 others

CompletedA Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic MelanomaThe purpose of this study is to determine the safety profile, pharmacokinetics, pharmacodynamics and maximum tolerated dose of RAF265 in patients with locally advanced and…NCT00304525·Aurora, Colorado and 10 others

RecruitingDESTINY-PANTUMOUR04This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior…NCT07124000·Birmingham, Alabama and 17 others

TerminatedNovel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular DiseaseThe purpose of this study is to understand the effect of vascular endothelial growth factor tyrosine kinase (VEGF) inhibitor, immune checkpoint-inhibitor (ICI), and combination…NCT03709771·Nashville, Tennessee

RecruitingSafety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisThis multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the…NCT06047379·Beverly Hills, California and 7 others

CompletedSL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasThis is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and…NCT03894618·Nashville, Tennessee and 4 others

CompletedEvaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic MelanomaThe primary objectives of this study are: * To explore the antitumor activity of MEDI-522 ± DTIC in patients with metastatic melanoma.NCT00066196·Scottsdale, Arizona and 24 others

CompletedMAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck CancersThis Phase 1 study is designed as a cell dose escalation trial in HLA-A\*02:01 and HLA-A\*02:06 subjects with MAGE-A10 positive urothelial, melanoma or head and neck tumors.NCT02989064·Boston, Massachusetts and 10 others

CompletedA Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors.NCT05708950·Santa Monica, California and 6 others

PreviousPage 16 of 18Next

Other Conditions in Tennessee

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma